Abstract
The primary objective of this review is to determine whether the use of mucoactive agents for ARF in critically ill patients is effective in improving clinically important outcomes including duration of ventilation and intubation rate. Secondary objectives include, to explore benefit in subgroups based on their reason for ARF, if any specific conditions benefit with a specific mucoactive agent, which mucoactive agent has most evidence and what outcomes are most frequently impacted.
Original language | English |
---|---|
Type | Protocol |
Publisher | PROSPERO |
Publication status | Published - 23 May 2018 |